Literature DB >> 12208767

Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia.

Zhigang Song1, Xiantuo Wu, William C Powell, Robert D Cardiff, Michael B Cohen, Robert T Tin, Robert J Matusik, Gary J Miller, Pradip Roy-Burman.   

Abstract

Fibroblast growth factor 8 isoform b (FGF8b), a mitogenic and transforming polypeptide, was demonstrated to be naturally up-regulated in prostatic premalignant and malignant lesions in men. We generated four independent lines of transgenic mice with targeted overexpression of FGF8b in the prostatic epithelium using an improved rat probasin promoter, ARR(2)PB. Transgene expression in the prostate tissue was readily demonstrated by reverse transcription-PCR and localized to the prostatic epithelium by in situ hybridization. The histopathology of the prostate tissues was followed in different age groups of the various lines but most extensively in one line (line 3), starting from 1 month of age up to 24 months. Prostatic hyperplasia appeared in the lateral and ventral prostates in some animals as early as 2-3 months and in other lobes between 6 and 16 months. Beginning at 5-7 months, dysplasia, akin to what may be considered low-grade prostatic intraepithelial neoplasia (LGPIN) in humans, was detected. During the first 14 months, 100% of animals exhibited multifocal epithelial hyperplasia; 35% also had areas of LGPIN. This profile changed in subsequent months (15-24 months) to a higher incidence of LGPIN (66%) along with high-grade PIN (HGPIN) lesions (51%). Similar to HGPIN, stromal proliferation and appearance of papillary hyperplasia with atypia displayed a delayed pattern. The affected stroma consisted primarily of the smooth muscle cell component. The incidence of chronic inflammation, mostly involving T cells, was higher in the prostate of the transgenic mice relative to controls; however, the presence of a direct correlation between inflammation and hyperplasia or preneoplastic lesions was not identified. These transgenic mice represent a "natural" animal model for investigating the mechanism of development and progression of prostatic diseases, such as prostatic hyperplasia and preneoplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Authors:  Teresa D Elo; Eeva M Valve; Jani A Seppänen; Heikki J Vuorikoski; Sari I Mäkelä; Matti Poutanen; Paula M Kujala; Pirkko L Härkönen
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  High-grade prostatic intraepithelial neoplasia.

Authors:  David G Bostwick; Lina Liu; Michael K Brawer; Junqi Qian
Journal:  Rev Urol       Date:  2004

3.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

4.  Cancer stem cells and microenvironment in prostate cancer progression.

Authors:  Chun-Peng Liao; Helty Adisetiyo; Mengmeng Liang; Pradip Roy-Burman
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

5.  Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma.

Authors:  Sang Hyun Lee; Shidong Jia; Yanni Zhu; Tamara Utermark; Sabina Signoretti; Massimo Loda; Brian Schaffhausen; Thomas M Roberts
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 6.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 7.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

8.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

Review 9.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

10.  Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.

Authors:  Caterina Nardella; Zhenbang Chen; Leonardo Salmena; Arkaitz Carracedo; Andrea Alimonti; Ainara Egia; Brett Carver; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Genes Dev       Date:  2008-08-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.